Xlife Sciences Expands Asian Footprint Through Strategic Partnerships in Digital Health and Precision Oncology
核心洞察
Xlife Sciences AG (搜索) has signed strategic partnerships with Korean companies Huraypositive Corp. (搜索) and OncoMASTER Inc. (搜索) to accelerate digital health and precision oncology innovation across Asia.
The collaboration leverages OncoMASTER's AI-powered platform built on clinical data from over 10,000 advanced cancer patients, representing the largest such dataset in Asia.
The partnership aims to bridge academic innovation with clinical translation while enabling Korean companies to access European commercialization opportunities through Xlife Sciences' network.
Swiss life sciences incubator Xlife Sciences AG (搜索) has forged strategic partnerships with two leading Korean healthcare companies to expand its presence in Asia's rapidly growing digital health and precision oncology markets. The company signed memorandums of understanding with digital health pioneer Huraypositive Corp. (搜索) and AI-powered oncology innovator OncoMASTER Inc. (搜索) in Seoul on June 16, 2025.
Leveraging Asia's Largest Cancer Dataset
The collaboration centers on OncoMASTER's substantial clinical database, which contains molecular and clinical data from more than 10,000 advanced cancer patients—representing the largest such dataset in Asia. This comprehensive resource enables the development of predictive algorithms designed to guide personalized treatment decisions, marking a significant shift from generalized therapies to individualized cancer care.
OncoMASTER's AI-based models focus on cancer treatment prediction, utilizing multi-omics technologies to analyze complex patient data. The company's data-driven approach aims to set new standards in oncology by accelerating the transition to precision medicine.
Digital Health Integration
Huraypositive brings over 15 years of experience in digital health solutions to the partnership, having introduced Korea's first digital chronic disease management platforms. The company collaborates with national health institutions and major corporate partners to advance personalized healthcare through artificial intelligence integration.
"As a pioneer in digital health in Korea, Huraypositive is excited to collaborate with global innovation leaders like Xlife Sciences and OncoMASTER," said Dooah Choi, CEO of Huraypositive. "By combining our digital health expertise with cutting-edge AI and precision health technologies, we aim to help shape a more connected, personalized healthcare ecosystem across Asia."
Three-Pillar Strategic Framework
The collaboration operates on three key strategic pillars designed to maximize synergies between the partners:
Expansion into Asia: Xlife Sciences will utilize Huraypositive's extensive healthcare ecosystem and OncoMASTER's domain expertise in AI-driven oncology to extend its footprint across Asian markets.
Innovation Acceleration: The parties will co-develop transformative healthcare platforms that integrate AI, digital health, and clinical insights to advance personalized care.
Global Market Access: Huraypositive and OncoMASTER will benefit from Xlife Sciences' academic and industrial network to explore commercialization opportunities in Europe.
Leadership Perspectives
Oliver R. Baumann, CEO of Xlife Sciences, emphasized the strategic importance of the partnership: "We are proud to enter this strategic alliance with Huraypositive and OncoMASTER, two forward-thinking leaders in digital health and precision oncology. This partnership underscores our commitment to expand internationally while accelerating development cycles through synergistic collaborations."
Woo Young Jang, CEO of OncoMASTER, highlighted the global expansion potential: "Through this collaboration, we aim to expand the global reach of our AI-based models for cancer treatment prediction and bring data-driven precision oncology to broader patient populations. We also look forward to enabling new translational pathways with the support of Xlife's network."
Broader Korean Market Strategy
This partnership represents part of Xlife Sciences' broader Korean market expansion strategy. Earlier in June 2025, the company also signed a strategic alliance with JIPYONG LLC (搜索), a premier Korean law firm, and JIPYONG IP (搜索), a leading intellectual property advisory firm, to facilitate Korean life sciences companies' access to international capital markets.
The combined partnerships position Xlife Sciences to serve as a bridge between Korean innovation and global markets, while simultaneously bringing international expertise to Asia's growing life sciences sector. The company focuses on four key areas: technological platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health.
Market Impact
The collaboration reflects the growing convergence of AI, digital health, and precision medicine in addressing unmet medical needs. By combining OncoMASTER's extensive patient dataset with Huraypositive's digital health infrastructure and Xlife Sciences' commercialization expertise, the partnership aims to accelerate the development and deployment of personalized healthcare solutions across multiple markets.
The agreement serves as a foundation for future joint initiatives and reflects a shared vision to redefine how healthcare innovation is developed and deployed across continents, with particular focus on bridging academic research with clinical translation in both Asian and European markets.